Gideon St Helen1, Kathryn C Ross2, Delia A Dempsey3, Christopher M Havel4, Peyton Jacob5, Neal L Benowitz6. 1. Assistant Professor, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA. 2. Postdoctoral fellow, Center for Tobacco Control Research and Education, University of California, San Francisco, CA. 3. Physician, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA. 4. Chemist, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA. 5. Research Chemist, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA. 6. Professor, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA.
Abstract
OBJECTIVE: To characterize vaping behavior and nicotine intake during ad libitum e-cigarette access. METHODS: Thirteen adult e-cigarette users had 90 minutes of videotaped ad libitum access to their usual e-cigarette. Plasma nicotine was measured before and every 15 minutes after the first puff; subjective effects were measured before and after the session. RESULTS: Average puff duration and interpuff interval were 3.5±1.4 seconds (±SD) and 118±141 seconds, respectively. 12% of puffs were unclustered puffs while 43%, 28%, and 17% were clustered in groups of 2-5, 6-10, and >10 puffs, respectively. On average, 4.0±3.3 mg of nicotine was inhaled; the maximum plasma nicotine concentration (Cmax) was 12.8±8.5 ng/mL. Among the 8 tank users, number of puffs was positively correlated with amount of nicotine inhaled, Cmax, and area under the plasma nicotine concentration-time curve (AUC0→90min) while interpuff interval was negatively correlated with Cmax and AUC0→90. CONCLUSION: Vaping patterns differ from cigarette smoking. Plasma nicotine levels were consistent with intermittent dosing of nicotine from e-cigarettes compared to the more bolus dosing from cigarettes. Differences in delivery patterns and peak levels of nicotine achieved could influence the addictiveness of e-cigarettes compared to conventional cigarettes.
OBJECTIVE: To characterize vaping behavior and nicotine intake during ad libitum e-cigarette access. METHODS: Thirteen adult e-cigarette users had 90 minutes of videotaped ad libitum access to their usual e-cigarette. Plasma nicotine was measured before and every 15 minutes after the first puff; subjective effects were measured before and after the session. RESULTS: Average puff duration and interpuff interval were 3.5±1.4 seconds (±SD) and 118±141 seconds, respectively. 12% of puffs were unclustered puffs while 43%, 28%, and 17% were clustered in groups of 2-5, 6-10, and >10 puffs, respectively. On average, 4.0±3.3 mg of nicotine was inhaled; the maximum plasma nicotine concentration (Cmax) was 12.8±8.5 ng/mL. Among the 8 tank users, number of puffs was positively correlated with amount of nicotine inhaled, Cmax, and area under the plasma nicotine concentration-time curve (AUC0→90min) while interpuff interval was negatively correlated with Cmax and AUC0→90. CONCLUSION: Vaping patterns differ from cigarette smoking. Plasma nicotine levels were consistent with intermittent dosing of nicotine from e-cigarettes compared to the more bolus dosing from cigarettes. Differences in delivery patterns and peak levels of nicotine achieved could influence the addictiveness of e-cigarettes compared to conventional cigarettes.
Authors: Jill M Williams; Kunal K Gandhi; Shou-En Lu; Supriya Kumar; Junwu Shen; Jonathan Foulds; Howard Kipen; Neal L Benowitz Journal: Nicotine Tob Res Date: 2010-06-28 Impact factor: 4.244
Authors: Frederick H Franken; Wallace B Pickworth; David H Epstein; Eric T Moolchan Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-01 Impact factor: 4.254
Authors: Cristina Miliano; E Reilly Scott; Laura B Murdaugh; Emma R Gnatowski; Christine L Faunce; Megan S Anderson; Malissa M Reyes; Ann M Gregus; Matthew W Buczynski Journal: J Neurosci Methods Date: 2019-10-12 Impact factor: 2.390
Authors: Gideon St Helen; Delia A Dempsey; Christopher M Havel; Peyton Jacob; Neal L Benowitz Journal: Drug Alcohol Depend Date: 2017-06-30 Impact factor: 4.492
Authors: Alexandra Noël; Christina M Verret; Farhana Hasan; Slawomir Lomnicki; John Morse; Annette Robichaud; Arthur L Penn Journal: J Vis Exp Date: 2018-08-25 Impact factor: 1.355
Authors: Walter Roberts; Terril Verplaetse; Mac Kenzie R Peltier; Kelly E Moore; Ralitza Gueorguieva; Sherry A McKee Journal: Addiction Date: 2020-02-09 Impact factor: 6.526